IPOs and Secondaries

IPOs and Secondaries Articles

Chinese online consumer finance platform LexinFintech has decided how it expects to price its 12 million American depositary shares in its initial public offering.
Two initial public offerings (IPOs) last week raised a combined $358 million, well below the anticipated level of $749 million. A total of four IPOs seeking $247 million in financing are on the...
Bluebird Bio saw its shares dip on Wednesday after the firm announced the pricing of a secondary offering of more than 3 million shares.
Chinese online consumer finance platform LexinFintech has amended its filing with the SEC regarding its initial public offering.
Three IPOs on this week's calendar include one biotech, one tech firm, and one commercial real estate company. Six IPOs were completed last week, including the largest biotech of the year.
Denali Therapeutics entered the markets with a bang on Friday. In its initial public offering, the company priced its almost 14 million shares within the expected range.
Consumer finance company CURO expects to price more than 6 million shares in the range that results in an initial public offering valued up to more than $122 million.
Life sciences company Quanterix intends to price more than 3 million shares in a range that results in an initial public offering valued up to more than $61 million.
Casa Systems expects to price more than 8 million shares in a range that results in an initial public offering valued up to more than $164 million.
Following a lull in IPOs around the Thanksgiving holiday, six companies will be looking to fire off IPOs in the coming week with a total capital raise target of more than $700 million.
Chinese e-commerce giant Alibaba filed a prospectus with the U.S. SEC for a bond offering estimated to total $5 to $7 billion.
Venator Materials shares remained relatively flat after the firm announced that it would be launching a secondary offering. The company is offering 18.0 million shares with an overallotment option...
Consumer finance company Curo Group intends to price more than 6 million shares to result in an initial public offering valued up to more than $122 million.
Odonate Therapeutics expects to price more than 5 million shares in a range that results in an initial public offering valued up to more than $182 million.
Neurodegenerative disease focused Denali Therapeutics intends to price more than 8 million shares in a range that results in an initial offering valued up to about $182 million.